Phase 3b, Randomized Trial of Continuous Revlimid (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst or Thalomid in Newly Diagnosed Multiple Myeloma

Trial Profile

Phase 3b, Randomized Trial of Continuous Revlimid (Lenalidomide) Therapy Versus Observation Following Induction Therapy That Does Not Include Revlimid, Pomalyst or Thalomid in Newly Diagnosed Multiple Myeloma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 21 Oct 2014 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top